ACM Global Laboratories, an affiliate of Rochester Regional Health, a large independent central lab, has introduced a new therapeutic service offering to support the specific testing needs of oncology clinical trials. ACM’s Smarter Testing for Oncology brings together key elements designed to optimize oncology clinical trial outcomes. The service comprises an in-house staff of subspecialty pathologists and access to a network of remote pathologists, image analytics and an extensive test menu of immunohistochemical and molecular testing. It also provides access to a range of general and subspecialty services in surgical pathology, cytopathology, and clinical pathology to support precision medicine in oncology research. 
           
With demand for pathological services in clinical trials on the rise and anatomic pathologists in increasingly short supply, access to subspecialized pathologists is becoming more critical. In response to this increased demand, ACM has developed Smarter Testing for Oncology to help deliver a unique service offering for clients conducting cancer research. Smarter Testing for Oncology is an extension of the company’s Smarter Testing consultative approach, which advocates working with sponsors and CROs to identify their endpoints and collaborate to find the optimal laboratory testing for their study. 
           
“We have been conducting testing for oncology trials for many years and recognized the power of bringing these individual components together in a complete package for our clients,” said Matthew Turner, MD, director of Pathology at ACM Global Laboratories. “Oncology trials have some distinct characteristics from other types of trials due to their complexity and need for biomarker analysis and companion diagnostics. Our team is ideally suited to address these trial nuances through our continuous exposure to complicated cancer resections that we see at Rochester Regional Health.”